Lipid nanoparticles for alkyl lysophospholipid edelfosine encapsulation: Development and in vitro characterization

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 68, Issue 2, 2008, Pages 207-213

  Estella Hermoso de Mendoza, Ander ^a   Rayo, Marta ^a   Mollinedo, Faustino ^b   Blanco Prieto, María J ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Atomic force microscopy; Differential scanning calorimetry; Drug delivery; Edelfosine; Lipid nanoparticles; X ray diffractometry

Indexed keywords

ALKYLLYSOPHOSPHOLIPID; CRYSTALLIN; EDELFOSINE; GLYCEROL BEHENATE; NANOPARTICLE; STEARIC ACID;

ARTICLE; ATOMIC FORCE MICROSCOPY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG RELEASE; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NANOENCAPSULATION; PARTICLE SIZE; PHOTON CORRELATION SPECTROSCOPY; X RAY DIFFRACTION; ZETA POTENTIAL;

CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; LIPIDS; MICROSCOPY, ATOMIC FORCE; NANOPARTICLES; PARTICLE SIZE; PHOSPHOLIPID ETHERS; X-RAY DIFFRACTION;

EID: 37849010813     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2007.06.015     Document Type: Article

References (31)

1. Gajate C., and Mollinedo F. Biological activities, mechanisms of action and biomedical prospect of the antitumor ether phospholipid ET-18-OCH3 (edelfosine), a proapoptotic agent in tumor cells. Curr. Drug Metab. 3 5 (2002) 491-525
2. Berdel W.E., Fink U., and Rastetter J. Clinical phase I pilot study of the alkyl lysophospholipid derivative ET-18-OCH3. Lipids 22 11 (1987) 967-969
3. Mollinedo F., et al. Selective induction of apoptosis in cancer cells by the ether lipid ET-18-OCH3 (Edelfosine): molecular structure requirements, cellular uptake, and protection by Bcl-2 and Bcl-X(L). Cancer Res. 57 7 (1997) 1320-1328
4. Gajate C., and Mollinedo F. Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts. Blood 109 2 (2007) 711-719
5. Mollinedo F. Antitumour ether lipids: proapoptotic agents with multiple therapeutic indications. Expert Opin. Therap. Patents 17 4 (2007) 385-405
6. Azzouz S., et al. Leishmanicidal activity of edelfosine, miltefosine and ilmofosine. Basic Clin. Pharmacol. Toxicol. 96 1 (2005) 60-65
7. Boggs K.P., Rock C.O., and Jackowski S. Lysophosphatidylcholine and 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine inhibit the CDP-choline pathway of phosphatidylcholine synthesis at the CTP:phosphocholine cytidylyltransferase step. J. Biol. Chem. 270 13 (1995) 7757-7764
8. Vogler W.R., et al. The anticancer drug edelfosine is a potent inhibitor of neovascularization in vivo. Cancer Invest. 16 8 (1998) 549-553
9. Zheng B., et al. Inhibition of protein kinase C, (sodium plus potassium)-activated adenosine triphosphatase, and sodium pump by synthetic phospholipid analogues. Cancer Res. 50 10 (1990) 3025-3031
10. Ahmad I., et al. Enhanced therapeutic effects of liposome-associated 1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphocholine. Cancer Res. 57 10 (1997) 1915-1921
11. Bhamra R., et al. Activity, pharmacokinetics and tissue distribution of TLC ELL-12 (liposomal antitumor ether lipid) in rats with transplantable, s.c. methylnitrosourea-induced tumors. Anticancer Drugs 14 6 (2003) 481-486
12. zur Muhlen A., Schwarz C., and Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery - drug release and release mechanism. Eur. J. Pharm. Biopharm. 45 2 (1998) 149-155
13. Siekmann B., and Westesen K. Sub-micron sized parenteral carrier systems based on solid lipids. Pharm. Pharmacol. Lett. 1 (1992) 123
14. Schwarz C., and Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery. II. Drug incorporation and physicochemical characterization. J. Microencapsul. 16 2 (1999) 205-213
15. de Vringer T., and de Ronde H.A. Preparation and structure of a water-in-oil cream containing lipid nanoparticles. J. Pharm. Sci. 84 4 (1995) 466-472
16. Almeida A.J., Runge S., and Muller R.H. Peptide-loaded solid lipid nanoparticles (SLN): influence of production parameters. Int. J. Pharm. 149 2 (1997) 255-265
17. Wissing S.A., Kayser O., and Muller R.H. Solid lipid nanoparticles for parenteral drug delivery. Adv. Drug Deliv. Rev. 56 9 (2004) 1257-1272
18. Mehnert W., and Mader K. Solid lipid nanoparticles: production, characterization and applications. Adv. Drug Deliv. Rev. 47 2-3 (2001) 165-196
19. Hu F.Q., et al. Preparation and characterization of stearic acid nanostructured lipid carriers by solvent diffusion method in an aqueous system. Colloids Surf. B Biointerfaces 45 3-4 (2005) 167-173
20. Jaspart S., et al. Solid lipid microparticles as a sustained release system for pulmonary drug delivery. Eur. J. Pharm. Biopharm. 65 1 (2007) 47-56
21. Muller R.H., Radtke M., and Wissing S.A. Nanostructured lipid matrices for improved microencapsulation of drugs. Int. J. Pharm. 242 1-2 (2002) 121-128
22. Freitas C., and Muller R.H. Effect of light and temperature on zeta potential and physical stability in solid lipid nanoparticles (SLN) dispersion. Int. J. Pharm. 168 (1998) 221-229
23. Cavalli R., et al. Sterilization and freeze-drying of drug-free and drug-loaded solid lipid nanoparticles. Int. J. Pharm. 148 (1997) 47-54
24. Blanco-Prieto M.J., Campanero M.A., and Mollinedo F. Quantitative determination of the antitumor alkyl ether phospholipid edelfosine by reversed-phase liquid chromatography-electrospray mass spectrometry: application to cell uptake studies and characterization of drug delivery systems. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 810 1 (2004) 85-92
25. Levy M.Y., et al. Characterization of diazepam submicron emulsion interface: role of oleic acid. J. Microencapsul. 11 1 (1994) 79-92
26. Chen H., et al. Podophyllotoxin-loaded solid lipid nanoparticles for epidermal targeting. J. Control Release 110 2 (2006) 296-306
27. Hu F.Q., et al. Preparation of solid lipid nanoparticles with clobetasol propionate by a novel solvent diffusion method in aqueous system and physicochemical characterization. Int. J. Pharm. 239 1-2 (2002) 121-128
28. Lee M.K., Lim S.J., and Kim C.K. Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles. Biomaterials 28 12 (2007) 2137-2146
29. Hou D., et al. The production and characteristics of solid lipid nanoparticles (SLNs). Biomaterials 24 10 (2003) 1781-1785
30. Souto E.B., Mehnert W., and Muller R.H. Polymorphic behaviour of Compritol888 ATO as bulk lipid and as SLN and NLC. J. Microencapsul. 23 4 (2006) 417-433
31. Olbrich C., and Muller R.H. Enzymatic degradation of SLN-effect of surfactant and surfactant mixtures. Int. J. Pharm. 180 1 (1999) 31-39